Payment overview · 2025
General Payments
$2,550.18
139 reported records · 23 companies
Healthcare provider profile · identity verified
Hal Jefferson Jenkins, MD
Allopathic & Osteopathic Physicians|Family Medicine · WHITE HOUSE, TN · NPI 1487674016
Verified facts
What the public records show
CMS Open Payments records show Hal Jefferson Jenkins, MD received $2,550.18 in general payments during 2025 across 139 reported records.
Novo Nordisk Inc accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $449.52 | 17.6% | 22 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $301.50 | 11.8% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $291.44 | 11.4% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $193.50 | 7.6% | 18 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $183.77 | 7.2% | 15 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $149.46 | 5.9% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $142.92 | 5.6% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $137.71 | 5.4% | 11 | 2025 |
| Pacira Pharmaceuticals Incorporated | Unresolved — no canonical attribution shown | $102.66 | 4.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $92.81 | 3.6% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.06 | 3.6% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $90.03 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $74.98 | 2.9% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.38 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $37.08 | 1.4% | 2 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.59 | 0.9% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $21.64 | 0.8% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $19.87 | 0.8% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.93 | 0.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.13 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.59 | 0.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.20 | 0.7% | 1 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $15.41 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,550.18 | 139 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $339.45 | 16 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $286.72 | 18 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $249.69 | 12 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $243.00 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $196.30 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $193.50 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $188.60 | 12 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $149.46 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $142.92 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $137.80 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $137.71 | 11 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $136.85 | 15 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $110.07 | 6 | 2025 |
Source payment records
|
|||||
| Exparel Normalized: exparel |
Drug | Pacira Pharmaceuticals Incorporated | $102.66 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $98.12 | 6 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $92.81 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $92.06 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.93 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $84.89 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $65.41 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $60.68 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.38 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $19.87 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $18.13 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.95 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $4.72 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $4.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $4.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 216 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 127 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 115 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 224 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 22 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
88 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
115 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
224 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
107 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 35 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
216 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 920 | 261 |
| Levothyroxine Sodium | Levothyroxine Sodium | 801 | 221 |
| Amlodipine Besylate | Amlodipine Besylate | 756 | 217 |
| Lisinopril | Lisinopril | 681 | 198 |
| Losartan Potassium | Losartan Potassium | 603 | 165 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 581 | 162 |
| Pantoprazole Sodium | Pantoprazole Sodium | 565 | 158 |
| Omeprazole | Omeprazole | 548 | 155 |
| Gabapentin | Gabapentin | 546 | 95 |
| Sertraline Hcl | Sertraline Hcl | 370 | 103 |
| Metformin Hcl | Metformin Hcl | 340 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 329 | 94 |
| Furosemide | Furosemide | 322 | 95 |
| Trazodone Hcl | Trazodone Hcl | 322 | 91 |
| Alprazolam | Alprazolam | 297 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 277 | 76 |
| Montelukast Sodium | Montelukast Sodium | 271 | 80 |
| Hydrochlorothiazide | Hydrochlorothiazide | 253 | 76 |
| Tamsulosin Hcl | Tamsulosin Hcl | 244 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 244 | 39 |
| Simvastatin | Simvastatin | 232 | 67 |
| Mounjaro | Tirzepatide | 224 | 41 |
| Eliquis | Apixaban | 216 | 43 |
| Pregabalin | Pregabalin | 213 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 209 | 62 |
| Carvedilol | Carvedilol | 202 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 202 | 77 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 53 |
| Meloxicam | Meloxicam | 199 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 197 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 171 | 45 |
| Clonazepam | Clonazepam | 167 | 31 |
| Glimepiride | Glimepiride | 166 | 42 |
| Xarelto | Rivaroxaban | 156 | 27 |
| Allopurinol | Allopurinol | 155 | 47 |
| Metformin Hcl Er | Metformin Hcl | 153 | 45 |
| Fluoxetine Hcl | Fluoxetine Hcl | 152 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 151 | 38 |
| Bupropion Xl | Bupropion Hcl | 150 | 39 |
| Ozempic | Semaglutide | 145 | 35 |
| Buspirone Hcl | Buspirone Hcl | 144 | 36 |
| Potassium Chloride | Potassium Chloride | 142 | 42 |
| Ezetimibe | Ezetimibe | 131 | 34 |
| Alendronate Sodium | Alendronate Sodium | 130 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 129 | 45 |
| Farxiga | Dapagliflozin Propanediol | 127 | 31 |
| Tramadol Hcl | Tramadol Hcl | 125 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 122 | 31 |
| Famotidine | Famotidine | 118 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 30 |
| Jardiance | Empagliflozin | 115 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 112 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 109 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 47 |
| Finasteride | Finasteride | 107 | 33 |
| Trulicity | Dulaglutide | 107 | 21 |
| Atenolol | Atenolol | 99 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 97 | 31 |
| Spironolactone | Spironolactone | 97 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 28 |
| Myrbetriq | Mirabegron | 88 | 24 |
| Temazepam | Temazepam | 88 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 88 | 23 |
| Donepezil Hcl | Donepezil Hcl | 84 | 19 |
| Diazepam | Diazepam | 80 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 24 |
| Prednisone | Prednisone | 79 | 41 |
| Lorazepam | Lorazepam | 77 | 16 |
| Terazosin Hcl | Terazosin Hcl | 76 | 22 |
| Estradiol | Estradiol | 75 | 23 |
| Lovastatin | Lovastatin | 75 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 65 |
| Warfarin Sodium | Warfarin Sodium | 72 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 71 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 23 |
| Synthroid | Levothyroxine Sodium | 68 | 22 |
| Azelastine Hcl | Azelastine Hcl | 67 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 20 |
| Fluconazole | Fluconazole | 60 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | 20 |
| Telmisartan | Telmisartan | 56 | 13 |
| Celecoxib | Celecoxib | 53 | 16 |
| Clonidine Hcl | Clonidine Hcl | 53 | 11 |
| Linzess | Linaclotide | 52 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 12 |
| Baclofen | Baclofen | 51 | suppressed |
| Bumetanide | Bumetanide | 49 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 49 | 24 |
| Nebivolol Hcl | Nebivolol Hcl | 48 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 21 |
| Valsartan | Valsartan | 47 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Mirtazapine | Mirtazapine | 46 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 31 |
| Chlorthalidone | Chlorthalidone | 41 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Irbesartan | Irbesartan | 39 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 18 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Methocarbamol | Methocarbamol | 36 | 11 |
| Promethazine Hcl | Promethazine Hcl | 36 | 11 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 12 |
| Primidone | Primidone | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Armodafinil | Armodafinil | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 27 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | 12 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 18 |
| Pentoxifylline | Pentoxifylline | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 11 |
| Azithromycin | Azithromycin | 19 | 16 |
| Glipizide Er | Glipizide | 19 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | 12 |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 13 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Quviviq | Daridorexant Hcl | 11 | suppressed |
| Tegretol Xr | Carbamazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,550.18 · 139 records | Novo Nordisk Inc | AFREZZA, AIRSUPRA, APTIMA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, Exparel, FARXIGA, Fluad, Flucelvax, GEMTESA, JARDIANCE, KRYSTEXXA, Korlym, MONOVISC, MOUNJARO, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, PROCLAIM, PROLIA, QULIPTA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, Tymlos, UBRELVY, VOQUEZNA, Veozah, Wegovy, Xembify, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error